Cell Processing Technologies Market Report 2025

The cell processing technologies market size has grown rapidly in recent years. It will grow from $4.29 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The growth during the historic period can be attributed to the increasing adoption of manual cell processing techniques, growing academic interest in cell biology research, the rise of early stem cell banking initiatives, expanding use of basic laboratory centrifugation tools, and rising demand for cell culture reagents in research.

The cell processing technologies market size is expected to see rapid growth in the next few years. It will grow to $8.15 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth during the forecast period can be attributed to the rising demand for personalized cell therapies, increasing investments in cell manufacturing infrastructure, expanding public and private sector funding, and a growing number of clinical trials for cell-based therapies. Key trends in the forecast period include advancements in smart bioreactor technologies, development of fully automated cell manufacturing systems, innovations in single-cell analysis platforms, progress in AI-driven quality control solutions, and the creation of integrated closed-loop processing workflows.

The increasing adoption of personalized medicine is expected to drive growth in the cell processing technologies market in the coming years. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve healthcare. Demand for personalized medicine is rising due to advancements in genomic technologies, which allow precise identification of genetic variations and enable targeted therapies. Cell processing technologies support personalized medicine by allowing accurate manipulation and preparation of patient-specific cells, ensuring high-quality, viable cells for tailored treatments. This enhances treatment outcomes and advances the development of effective, targeted interventions. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the growing adoption of personalized therapies is fueling the cell processing technologies market.

Key players in the cell processing technologies market are focusing on advanced solutions, such as automated cell therapy manufacturing platforms, to improve scalability, process efficiency, cell quality, and reduce production costs. An automated cell therapy manufacturing platform is a fully integrated system that employs robotics, sensors, and software to perform the complete production process of cell-based therapies with minimal manual intervention. For instance, in March 2025, Limula SA, a Switzerland-based life sciences company, launched LimONE, a fully automated platform designed to transform the manufacturing of advanced therapies, including CAR-T and gene-edited stem cells. LimONE integrates a bioreactor and centrifuge into a single closed system using one consumable throughout all development stages, streamlining complex manufacturing processes. The platform allows hospitals, biotech firms, and manufacturers to accelerate the transition from research to clinical trials and commercial production, making personalized cell and gene therapies more widely accessible.

In June 2025, StemCell Technologies Canada Inc., a Canada-based biotechnology company, acquired Cellular Highways Ltd. for an undisclosed amount. This acquisition aims to strengthen StemCell’s cell therapy manufacturing capabilities by integrating Cellular Highways’ advanced cell sorting technology, including the VACS-powered Highway1 instrument. Cellular Highways Ltd., based in the UK, specializes in cell processing technologies for both research and therapeutic applications.

Major players in the cell processing technologies market are Thermo Fisher Scientific Inc., Fresenius SE, Danaher Corporation, Cryo-Cell International Inc., Merck KGaA, Becton Dickinson and Company, GE HealthCare Technologies Inc., Lonza Group AG, Terumo Corporation, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Americord Registry LLC, Bio-Rad Laboratories Inc., PHC Holdings Corporation, Bio-Techne Corporation, StemCell Technologies Inc., Shibuya Corporation, Repligen Corporation, Beckman Coulter Inc., ThermoGenesis Holdings Inc., Ori Biotech Ltd., Biospherix Ltd., Miltenyi Biotec B.V. & Co. KG.

North America was the largest region in the cell processing technologies market in 2024. The regions covered in cell processing technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell processing technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cell processing technologies encompass a range of methods and tools used to isolate, manipulate, expand, and prepare living cells for research, therapeutic, or diagnostic purposes. Their primary objective is to ensure precise handling and modification of cells while preserving their viability, functionality, and safety for applications in regenerative medicine, cell therapy, or laboratory studies.

The primary product categories in cell processing technologies include equipment, consumables, and software. Cell processing equipment consists of specialized instruments and devices designed to manipulate, culture, separate, and prepare living cells for research, therapeutic, or clinical use. These technologies are applied in areas such as oncology, cardiovascular disease, bone repair, neurological disorders, skeletal muscle repair, and immune diseases, serving diverse end users including pharmaceutical and biotechnology companies, academic research institutes, and others.

The cell processing technologies market research report is one of a series of new reports that provides cell processing technologies market statistics, including cell processing technologies industry global market size, regional shares, competitors with a cell processing technologies market share, detailed cell processing technologies market segments, market trends and opportunities, and any further data you may need to thrive in the cell processing technologies industry. This cell processing technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell processing technologies market consists of revenues earned by entities by providing services such as cell isolation, purification, culture, expansion, genetic modification, quality control testing, and cryopreservation. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell processing technologies market also includes sales of cell isolation instruments, automated bioreactors, closed-system processing units, cell counting and analysis devices, and cryopreservation equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.